Divi's Labs Q3 FY26: Revenue up 12%, PAT Rs 598 cr standalone
DIVISLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.8 pts more than Nifty 100 and 3.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Divi's Labs reported Q3 FY26 standalone revenue of Rs 2,578 cr (up 12.2% YoY from Rs 2,297 cr) and total income of Rs 2,665 cr. Standalone PAT was Rs 598 cr vs Rs 594 cr YoY. An exceptional item of Rs 74 cr was booked for the one-time impact of new Labour Codes, otherwise PBT grew 19.5% to Rs 872 cr. Consolidated PAT was Rs 583 cr vs Rs 589 cr. For 9M FY26, standalone PAT grew about 20% to Rs 1,851 cr. Forex gain of Rs 18 cr in Q3. Auditors Price Waterhouse issued unmodified review reports.
Revenue grew double-digits YoY but Labour Codes exceptional charge of Rs 74 cr trimmed reported PBT by about 8.5%; underlying earnings remain healthy.